Pediatric Oncology

NCI-CCC Tumor Board Question

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?

In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?

J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024

2 Answers available

Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?

1 Answer available

How would you manage asymptomatic brain metastases from testicular non-seminomatous germ cell tumor with a choriocarcinomatous component?

2 Answers available

What is the preferred regimen for AYA patients with T-Cell Lymphoblastic Lymphoma?

1 Answer available

How would you treat stage II pediatric type follicular lymphoma that is not amenable to surgical resection in an adolescent and young adult patient?

1 Answer available

What dose of PEG-asparaginase do you recommend for teens with high BMI treated on a pediatric ALL regimen?

Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...

2 Answers available

Should a teenager diagnosed with CML in blast crisis go to transplant once MRD is negative?

2 Answers available

What treatment regimen would you recommend for young adults with platinum refractory relapsed germ cell tumors?

2 Answers available

Should high-dose methotrexate be used in the treatment of AYA patients with osteosarcoma?

2 Answers available

What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?

1 Answer available

Should end-of-therapy echocardiograms be obtained for AYA patients with sarcomas who have received high-dose anthracyclines?

At what frequency and for how long should echos be monitored?

1 Answer available

How do you choose first or second-line systemic therapy for fibrolamellar hepatocellular carcinoma?

What are there most evidence-based options?

1 Answer available

Papers discussed in this category

Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Oncologist, 2020 Mar 10

Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

Semin Diagn Pathol, 2016 Dec 23

Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.

Journal of the National Comprehensive Cancer Network : JNCCN, 2018-01

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Cancer medicine, 2019-01

Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.

Journal of the National Cancer Institute, 1988-07-06

The role of methotrexate in osteosarcoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

Anticancer Drugs,

Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma.

J Adolesc Young Adult Oncol, 2019 Nov 08

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

N. Engl. J. Med., 2018-01-25

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Ann Oncol, 2007 Nov 15

Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.

Biol Blood Marrow Transplant, 2019 Jul 01

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.

Ann Hematol, 2015 Mar 27

Management of chronic myeloid leukemia in blast crisis.

Leukemia, 2008-12

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

Leuk Lymphoma, 2019 Nov 04

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Zhonghua Bing Li Xue Za Zhi,

[Clinicopathological characteristics of pediatric-type follicular lymphomas: an analysis of 37 cases].

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01

Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.

Cancer, 2020 Mar 15

High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases.

J Clin Oncol, 2021 Apr 06

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.

British journal of haematology, 2014-06

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.

International journal of radiation oncology, biology, physics, 2019-06-01

Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Blood, 2018-07-05

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

Blood,

Getting to transplant in Hodgkin lymphoma: BVB.

Blood,

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.

J Clin Oncol, 2021 Jun 25

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.

Pediatric Oncology

NCI-CCC Tumor Board Question

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Oncology